Reference
- Mehnert JM, Mitchell T, Huang AC, et al. BAMM (BRAF autophagy and MEK inhibition in melanoma): a phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600-mutant melanoma. Clin Cancer Res. 2022 Jan 12:clincanres.3382.2021. Online ahead of print. PMID: 35022320. DOI:https://doi.org/10.1158/1078-0432.CCR-21-3382.